Class / Patent application number | Description | Number of patent applications / Date published |
424235100 | Transposon mutant or deletion mutant bacterium (e.g., produced by transposon mutagenesis, etc.) | 27 |
20080248065 | Gna1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis - The present invention generally provides methods and compositions for eliciting an immune response against | 10-09-2008 |
20090196887 | Immunogenic Compositions for Activating Gamma Delta T Cells - Disclosed are compositions, kits, and methods for activating, expanding, or stimulating γδ T cells that include recombinant attenuated microbes. The compositions may include pharmaceutical compositions that are used as γδ T cell stimulating vaccines or immunogenic compositions for preventing or treating microbial infections and hyperplasias such as cancer. | 08-06-2009 |
20090297560 | Oral vaccine for Borrelia - The present invention relates to vaccines for control of | 12-03-2009 |
20100068230 | MODIFIED FREE-LIVING MICROBES, VACCINE COMPOSITIONS AND METHODS OF USE THEREOF - Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases. | 03-18-2010 |
20100129406 | HOLIN-ENHANCED VACCINES AND REAGENTS, AND METHODS OF USE THEREOF - The invention provides | 05-27-2010 |
20100322974 | Targeting the histone code as a bacterial strategy for selectively modulating gene expression - The ospF gene of | 12-23-2010 |
20110008389 | RECOMBINANT ATTENUATED CLOSTRIDIUM ORGANISMS AND VACCINE - The present invention discloses attenuated | 01-13-2011 |
20110104205 | HETEROLOGOUS PROTECTION AGAINST PASTEURELLA MULTOCIDA PROVIDED BY P. MULTOCIDA FUR CELLS AND THE OUTER-MEMBRANE PROTEIN EXTRACTS THEREOF - The invention relates to | 05-05-2011 |
20110117132 | MUTATED SALMONELLA TYPHI STRAIN AND USE THEREOF IN A VACCINE - The present invention relates to an attenuated | 05-19-2011 |
20110182942 | MENINGOCOCCAL MULTIVALENT NATIVE OUTER MEMBRANE VESICLE VACCINE, METHODS OF MAKING AND USE THEREOF - The present technology provides vaccine compositions comprising native outer membrane vesicles (NOMVs) from at least one genetically modified strain of | 07-28-2011 |
20110195092 | LIVE ATTENUATED ALDOLASE-NEGATIVE BACTERIAL VACCINE - The present invention relates to live attenuated bacteria for use in a medicament. The invention also relates to vaccines based upon such bacteria useful for the prevention of microbial pathogenesis and to the use of such bacteria for the manufacture of a vaccine. Finally, the invention relates to methods for the preparation of such vaccines. | 08-11-2011 |
20110200638 | BACTERIAL VACCINE - A bacterial cell which expresses three or more coli surface (CS) antigens and methods of making such a cell. The cell is useful in making vaccines against diarrhea. | 08-18-2011 |
20110287055 | COMPOSITIONS COMPRISING PRFA* MUTANT LISTERIA AND MEHTODS OF USE THEREOF - The invention provides recombinant | 11-24-2011 |
20110293662 | COMPOSITIONS COMPRISING REDUCED GENOME BACTERIA FOR USE IN TREATMENT OF SEPSIS - Methods for prophylaxis or treatment of sepsis in a subject are provided comprising administering to the subject a therapeutically effective dose of multiple deletion strain bacteria. | 12-01-2011 |
20120107360 | GAMMA-GLUTAMYL TRANSPEPTIDASE ATTENUATED FRANCISELLA - The present invention relates to a mutated | 05-03-2012 |
20120294892 | Avirulent Salmonella Gallinarum Variants and Pharmaceutical Composition Using the Same - The present invention relates to avirulent | 11-22-2012 |
20130017218 | LIVE BACTERIAL VACCINE SAFETY - The present invention provides for a method of reducing the reactogenicity of live attentuated bacterial vaccines by deleting at least a portion (e.g., the TLR-5 stimulating domain of a flagellin protein) of at least one of the bacterial genes that encodes a flagellin from the bacterium genome. These vaccines are directed against enteric or non-enteric flagellin-producing bacteria. A particular embodiment provides for a live attenuated cholera vaccine having reduced reactogenicity. | 01-17-2013 |
20130295136 | LIVE ATTENUATED CATFISH VACCINE AND METHOD OF MAKING - A high throughput bioluminescence mutant screening procedure is disclosed. This procedure utilizes robotics, and bacterial luciferase to allow real-time monitoring of mutant viability. The procedure was used to decelop a live attenuated vaccine for a catfish against | 11-07-2013 |
20140186398 | BACTERIAL RNAs AS VACCINE ADJUVANTS - The disclosure features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants. More specifically, the disclosure provides a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium), a tumor antigen, or an immunogenic peptide of microbial or mammalian origin, and an adjuvant, wherein adjuvant comprises prokaryotic mRNA (e.g., bacterial mRNA), as well as the methods of using the vaccine compositions. Further disclosed are the structural features of the prokaryotic mRNA used as the adjuvants. | 07-03-2014 |
20150140038 | MYCOBACTERIUM TUBERCULOSIS DeltaESX-3 MUTANTS - Isolated mutant | 05-21-2015 |
20150297701 | Interferon-beta Production Modulating Listeria Strains and Methods for Using Same | 10-22-2015 |
20160017312 | METHOD FOR MODULATING A BACTERIAL INVASION SWITCH - The subject matter disclosed herein pertains to the modulation of a bacterial invasion switch and the subsequent use of the bacterium to vaccinate an organism. In one embodiment, the bacterial invasion switch is modulated by changing the proteolysis of ExoR protein. In another embodiment, a mutated bacterium produces a mutant ExoR protein that resists proteolysis. | 01-21-2016 |
20160067323 | Francisella tularensis Live Vaccine Strains and Methods of Use - The present invention includes live strain of | 03-10-2016 |
20160095914 | Adenylate Cyclase Deficient Bordetella Strains - A CyaA-deficient | 04-07-2016 |
20160144012 | LIVE-ATTENUATED COMPOSITIONS FOR BACTERIAL INFECTIONS - The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity. | 05-26-2016 |
20160184419 | RECOMBINANT MYCOBACTERIUM AS A VACCINE - The invention relates to a recombinant | 06-30-2016 |
20180021421 | ATTENUATED VACCINES TO PROTECT AGAINST TICK-BORNE EHRLICHIA SPECIES INFECTIONS | 01-25-2018 |